Atsena Therapeutics Inc.
Atsena Therapeutics Inc.
Explore linked clinical trials.2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis | eye disorder, retinal degeneration, retinal disorder, retinoschisis | Recruiting | Phase 3 | 2026-09-29 | NCT05878860 | |
| Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D | Eye Diseases, Hereditary, Leber congenital amaurosis, Leber congenital amaurosis 1, cone-rod dystrophy 6, eye disorder, littoral cell angioma of the spleen, retinal disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-03 | NCT03920007 |